Eventide Asset Management — Portfolio, Funds & Investments

We track Eventide Asset Management but have little verified detail yet.

Portfolio

1 total

Recent Investment Activity

Track record: led 0 and participated in 1 of 1 tracked venture round · 1 in the last 12 months

Date	Company	Event	Role	Amount	Valuation	Investors	Source
Jun 30, 2026	Flare Therapeutics	Series C	Participated	$85M	—	Third Rock VenturesLeadNextech InvestLeadPfizer VenturesEli LillyNovartisBoxer CapitalGordonMD Global InvestmentsInvusCasdin CapitalAgent CapitalEventide Asset Management	Pulse story

Co-Investors

Boxer Capital · 1 shared Casdin Capital · 1 shared Eli Lilly · 1 shared Eli Lilly and Company · 1 shared GordonMD Global Investments · 1 shared Invus · 1 shared Nextech Invest · 1 shared Pfizer Ventures · 1 shared Third Rock Ventures · 1 shared

Latest Pulse

Jun 30, 2026Flare Therapeutics Raises $85M, Names New CEOFlare Therapeutics closed an $85 million insider-led Series C and named Anna Protopapas CEO, funding its first-in-class ARON-targeting degrader for prostate cancer toward a Phase 1A trial expected in Q3 2026.→

Eventide Asset Management FAQ

What companies has Eventide Asset Management invested in?

Eventide Asset Management's portfolio includes Flare Therapeutics.

Who does Eventide Asset Management co-invest with most?

In the rounds Value Add tracks, Eventide Asset Management most often invests alongside Boxer Capital (1 shared deal), Casdin Capital (1 shared deal), Eli Lilly (1 shared deal), Eli Lilly and Company (1 shared deal), GordonMD Global Investments (1 shared deal).

Sources & methodologyshow

Where these figures come from

GlobeNewswireprimary source1 fact

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction